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Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present
with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common
and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the
risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in
patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced
breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating
agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes. This review summarizes key
milestones in the evolution of adjuvant systemic therapy in general, and adjuvant chemotherapy in particular.
Although adjuvant treatments are routinely guided by predictive factors for endocrine therapy (hormone receptor
expression) and anti-HER2 therapy (HER2 overexpression), predicting benefit from chemotherapy has been more
challenging. Randomized studies are now in progress utilizing multiparameter gene expression assays that may more
accurately select patients most likely to benefit from adjuvant chemotherapy.
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Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death among women,
accounting for 25 % of the total cancer cases (1.68 million)
and 15 % of the cancer deaths (520,000) worldwide [1, 2].
In the United States, it is estimated that there will be
231,840 new cases of invasive breast cancer and 40,290
deaths from the disease in 2015, and that one in eight
women will develop breast cancer during their lifetime [3].
The disease is localized to the breast at presentation in
61 % of cases, regionally advanced in 32 %, and metastatic
in 7 % [4]. When localized or regionally advanced, the dis-
ease is potentially curable with local and systemic therapy.
Adjuvant systemic therapies reduce the risk of distant re-
currence, presumably by treating micro-metastatic disease
that may not be clinically evident at the time of local ther-
apy. Prognostic factors for distant recurrence irrespective
of treatment include classical clinicopathologic features
such as tumor size, tumor grade, and number of axillary
lymph nodes with metastasis. Predictive factors that identify* Correspondence: janampa@montefiore.org
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estrogen receptor (ER) and progesterone receptor (PR),
which identify patients who benefit from adjuvant endo-
crine therapy [5], and overexpression of human epidermal
growth factor receptor 2 (HER2) protein (or HER2 gene
amplification) [6], which identifies patients who benefit
from adjuvant HER2-directed therapy. Multiparameter
gene expression assays may also provide both prognostic
information and prediction of benefit from adjuvant
chemotherapy in patients with ER-positive disease [7, 8].An abbreviated history of adjuvant systemic therapy
The initial approach to therapy for breast cancer was
based on the premise that the disease metastasized via
locoregional spread in an orderly fashion, and thus could
be cured with aggressive surgery. The radical mastec-
tomy was thus the standard surgical procedure for breast
cancer in the early 20th century [9]. Randomized trials
subsequently showed no benefit from radical mastec-
tomy compared with less aggressive surgical procedures,
and demonstrated that distant recurrence remained a
major clinical problem irrespective of the primary surgical
therapy [10, 11].icle is distributed under the terms of the Creative Commons Attribution 4.0
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Box 1. Milestones in the adjuvant therapy of breast
cancer
Chemotherapy
 Alkylating agents (thiotepa, L-phenylalinine mustard) given
after surgery decrease recurrence rates [20, 21]
 Adjuvant polychemotherapy “CMF” regimen substantially
reduces risk of recurrence [22] and improves survival [12, 25]
 National Institute of Health consensus panel recommends
that adjuvant polychemotherapy be recommended to the
majority of women with localized breast cancer regardless of
lymph node, menopausal, or hormone receptor status [27]
 Anthracyclines and taxanes integrated into adjuvant
chemotherapy regimens produce additional survival gains [16]
 Multiparameter gene expression assays identify subsets of
patients with ER-positive disease who derive greatest benefit
from adjuvant chemotherapy [29, 30] and are incorporated
into evidence-based guidelines [31]
Endocrine therapy
 Adjuvant tamoxifen reduces recurrence [32] and improve
survival [12, 33]
 Five years of adjuvant tamoxifen therapy more effective than
shorter durations [13]
 The proportional benefits of endocrine therapy are similar
irrespective of nodal metastasis and that the benefits are
seen only in patients with ER-positive tumors [15]
 Aromatase inhibitors are more effective than tamoxifen in
postmenopausal women [34, 35]
 Extended adjuvant therapy for up to 10 years more effective
than 5 years of therapy, including sequential tamoxifen
followed by aromatase inhibitor [36], or tamoxifen for up to
10 years [37]
 Ovarian suppression plus an aromatase inhibitor was shown
to be more effective than tamoxifen in premenopausal
women at high risk for recurrence [38, 39]
Anti-HER2 therapy
 Adjuvant trastuzumab reduces the risk of recurrence when
added to adjuvant chemotherapy, given either concurrently
or sequentially, in patients with HER2 overexpressing node-
positive or high-risk node-negative breast cancer [43]
 One year of trastuzumab was more effective than 6 months
[46], 2 years of therapy was no more effective than 1 year [47]
 Addition of the HER2 tyrosine kinase inhibitor did not
improve outcomes when added to trastuzumab [48]
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aggressive to less aggressive, the types of adjuvant sys-
temic therapies and their indications expanded. A series
of seminal clinical trials demonstrated that adjuvant sys-
temic chemotherapy, endocrine therapy, and anti-HER2
directed therapy substantially reduced the risk of recur-
rence and improved overall survival when added to local
therapy. In addition to the milestones achieved by indi-
vidual trials summarized in Box 1, the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) has
periodically reported meta-analyses of all clinical trials
with available data that have added to our knowledge
about the benefits of adjuvant systemic therapy [12–16].
Based upon the improvements in outcomes associated
with systemic therapies described below, current adjuvant
therapy options summarized in Table 1 are commonly
tailored to four phenotypic subtypes that are defined in
a practical manner by utilizing information on ER, PR,
and HER2 expression. This practical phenotypic classifica-
tion roughly corresponds to “intrinsic subtypes” identified
by gene expression profiling [17], although the latter
classification may provide more accurate prognostic
and predictive information [18, 19].
The first randomized trial evaluating adjuvant chemo-
therapy in breast cancer was the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B-01 trial initiated in
1958, which reported in 1968 that an adjuvant alkylating
agent (thiotepa) given after radical mastectomy significantly
decreased recurrence rate in pre-menopausal women with
four or more positive axillary lymph nodes [20]. A subse-
quent randomized study reported in 1975 showed benefit
from another alkylating agent (L-phenylalinine mustard)
[21]. Other reports from the Istituto Nazionale Tumori in
Milan, Italy, showed that combination chemotherapy
regimen called “CMF” including an alkylating agent
(cyclophosphamide) and antimetabolites (methotrexate
and 5-fluorouracil) significantly reduced the risk of recur-
rence [22], thus ushering in the modern age of adjuvant
polychemotherapy regimens that are now commonly used
in clinical practice. These trials were among the first to
establish a role for adjuvant chemotherapy, initially in
premenopausal women with axillary node-positive disease
at highest risk for recurrence [22], with subsequent trials
also showing benefit in lower risk post-menopausal women
[23] and women with axillary node-negative disease
[24–26]. In 2001, a National Institute of Health consensus
panel in the US concluded: “Because adjuvant polyche-
motherapy improves survival, it should be recommended
to the majority of women with localized breast cancer re-
gardless of lymph node, menopausal, or hormone receptor
status.” [27] Although the widespread adoption of more
effective systemic therapies contributed to declining breast
cancer mortality rates in the US and globally [1, 28], it
also resulted in many patients being unintentionally
Table 1 Systemic adjuvant therapy options for operable breast cancer
Breast cancer subtype/classification Adjuvant systemic therapy
Phenotypic subtype Intrinsic subtype Endocrine therapy Anti-HER2 therapy Chemotherapy
Hormone receptors HER2 overexpression
+ – Luminal A or B Yes No Yes (if high risk)
+ + Luminal B or HER2 enriched Yes Yes Yes
– – Basal No No Yes
– + HER2 enriched No Yes Yes
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may been cured without it. Several multiparameter
gene expression assays have recently been shown to
provide prognostic information in patients with ER-
positive breast cancer [7, 8] and also identify which
patients derive greatest benefit from adjuvant chemo-
therapy [29, 30]. Some of these assays are endorsed by
evidence-based guidelines for making clinical decisions
regarding the use of adjuvant chemotherapy in specific
settings [31].
Approximately 75 % of all breast cancers express hor-
mone receptors [5]. Endocrine therapy reduces the risk
of recurrence in hormone receptor-expressing disease,
whether used alone or in addition to chemotherapy. In
1982, adjuvant tamoxifen given for 2 years was shown to
reduce the risk of recurrence [32] and improve survival
[33]. Subsequent studies and a meta-analyses of these
studies confirmed a survival benefit [12], and also showed
that 5 years of therapy was more effective than shorter du-
rations, the proportional benefits were similar irrespective
of nodal metastasis, and that the benefits were seen only in
patients with ER-positive tumors [13, 15]. Aromatase inhib-
itors were subsequently shown to be more effective than
tamoxifen in postmenopausal women [34, 35]. In addition,
extended adjuvant therapy for up to 10 years was shown to
be more effective than 5 years of therapy, including sequen-
tial tamoxifen followed by an aromatase inhibitor [36], or
tamoxifen for up to 10 years [37]. Finally, in premenopausal
women at high risk for recurrence, ovarian suppression
plus an aromatase inhibitor was shown to be more effective
than tamoxifen [38, 39].
Approximately 25 % of all breast cancers overexpress
the HER2 oncogene [6]. In 2005, several randomized
trials demonstrated that addition of the anti-HER2
antibody trastuzumab to adjuvant chemotherapy, either
concurrently or sequentially, substantially decreased the
risk of recurrence in patients with HER2 overexpressing
node-positive or high-risk node-negative breast cancer
[40–43]. Addition of trastuzumab to sequential anthracy-
cline/cyclophosphamide-taxane was associated with about
a 3 % risk of cardiac toxicity [40–42], while the combin-
ation of trastuzumab with non-anthracycline regimens
(e.g. carboplatin/docetaxel) was associated with lower rates
of cardiac toxicity [43]. Non-randomized single arm studieshave also shown excellent outcomes in patients with lower
risk node-negative disease not included in other studies
who would have been expected to have higher recurrence
rates without adjuvant trastuzumab [44, 45]. Subsequent
studies demonstrated that 1 year of trastuzumab was more
effective than 6 months [46], but 2 years of therapy was no
more effective than 1 year [47]. The addition of the HER2
tyrosine kinase inhibitor lapatinib did not improve out-
comes when added to trastuzumab [48].
Adjuvant chemotherapy: first, second, and third
generation regimens
Adjuvant! is a web-based decision aid commonly used in
clinical practice that allows clinicians and patients to
better understand the potential benefits of adjuvant ther-
apy, especially chemotherapy [49]. Estimates provided by
Adjuvant! have been shown to correlate closely with ac-
tual clinical outcomes in population- and hospital-based
cohorts [50, 51]. Adjuvant! classifies adjuvant chemotherapy
regimens as first, second, and third-generation, as exempli-
fied in Table 2. A modification of this classification will be
used here to categorize the numerous chemotherapy
regimens discussed in this review, and to describe the
clinical trials summarized in Table 3. The regimens used
in these studies generally included anthracyclines (doxo-
rubicin, epirubicin) and/or taxanes (paclitaxel, docetaxel),
which are the two most active classes of cytotoxic agents
for both early and advanced stage breast cancer.
Anthracyclines
Anthracyclines, derivatives of the antibiotic rhodomycin
B, were initially isolated in the 1950s from gram-positive
Streptomyces present in an Indian soil sample [52].
Doxorubicin was isolated from Streptomyces peucetius
[53], a mutant of the original Streptomyces strain found
near the Adriatic sea, and was therefore named Adria-
mycin. Doxorubicin was found to be one of the most
active single cytotoxic agents in metastatic breast cancer
[54, 55], although congestive cardiomyopathy emerged as
a toxicity that required limiting the cumulative lifetime
dose in order to minimize the risk of this toxicity [56].
Epirubicin, an epimer of doxorubicin differing in the
orientation of the C4 hydroxyl group on the sugar, is a less
cardiotoxic anthracycline than doxorubicin [57, 58].
Table 2 Classification of adjuvant chemotherapy regimens
Generation* Benefit Regimens with substantial evidence base
First 35 % reduction in breast cancer mortality compared with no adjuvant chemotherapy CMFx6, ACx4, FEC50x6
Second 20 % reduction in breast cancer mortality compared with first generation regimen FEC100x6, CAFx6, FACx6
ACx4-Tx4 (q3wks)
DCx4, Ex4-CMFx4




ACx4-docetaxel (q 3 weeks)
*Adopted from Adjuvant online with modifications [50, 51]
CMF, Cyclophosphamide, methotrexate, 5-flourouracil; AC, Doxorubicin, cyclophosphamide; FEC50, 5-flourouracil, epirubicin (50 mg/m2), cyclophosphamide;
FEC100, 5-flourouracil, epirubicin (100 mg/m2), cyclophosphamide; DC, Docetaxel, cyclophosphamide; CAF, Cyclophosphamide, doxorubicin, 5-flourouracil;
FAC, 5-flouroracil, doxorubicin, cyclophosphamide; DAC, Docetaxel, doxorubicin, cyclophosphamide; T, paclitaxel; D, Docetaxel; E, Epirubicin
Table 3 Select phase III trials of first, second, and third generation trials




Hazard ratio for disease-free
survival
Hazard ratio for overall
survival
First CMF vs no chemo [22, 71] Positive 386 28.5 0.71 (P = 0.005) 0.79 (P = 0.04)
CMF + Tam vs Tam (B20)
[26]
Negative 2306 5 0.65 (P = 0.001) 0.64 (P = 0.03)
AC vs CMF (B15) [72, 73] Positive 2194 3 P = 0.5* P = 0.8*
AC vs CMF (B23) [74] Negative 2008 5 P = 0.9* P = 0.4*
FEC50 + Tam vs Tam [76] Positive 457 9.4 0.46 (P = 0.0008) 0.65 (P = 0.07)
Second FEC100 vs FEC50 [78] Positive 546 5.6 0.63 (P = 0.02) 0.45 (P = 0.005)
ACx4-Tx4 vs ACx4 (C9344)
[82]
Positive 3121 5.8 0.83 (P = 0.002) 0.82 (P = 0.006)
ACx4-Tx4 vs ACx4 (B28)
[83]
Positive 3060 5.4 0.83 (P = 0.006) 0.93 (P = 0.46)





2391 4 0.69 (P <0.001) 0.67 (P <0.001)
Third DAC vs FAC [89, 112] Positive 1491 10.3 0.80 (P = 0.004) 0.74 (P = 0.002)
DAC vs FAC [91] Negative 1060 6.4 0.68 (P = 0.01) 0.76 (P = 0.29)
FEC-D vs FEC [92, 93] Positive 1099 7.8 0.85 (P = 0.036) 0.75 (P = 0.007)
FEC-weekly T vs FEC [95] Positive 1246 5.5 0.77 (P = 0.022) 0.78 (P = 0.11)
FAC-weekly T vs FAC [113] Negative 1925 5.3 0.73 (P = 0.04) 0.79 (P = 0.31)
Q3 vs q2wk ACT [97, 98] Positive 2005 5.8 0.80 (P = 0.01) 0.85 (P = 0.04)
AC-T vs AC-weekly T
[100, 101]
Positive 4954 12.1 0.84 (P = 0.011) 0.87 (P = 0.09)
AC-T vs AC-D 0.79 (P = 0.001 0.86 (P = 0.054)
AC-D vs DAC [103] Positive 5351 6.1 0.83 (P = 0.01) 0.86 (P = 0.09)
AC-D vs AD 0.80 (P = 0.001) 0.83 (P = 0.03)
CMF, Cyclophosphamide, methotrexate, 5-flourouracil; AC, Doxorubicin, cyclophosphamide; FEC50, 5-flourouracil, epirubicin (50 mg/m2), cyclophosphamide;
FEC100, 5-flourouracil, epirubicin (100 mg/m2), cyclophosphamide; DC, Docetaxel, cyclophosphamide; CAF, Cyclophosphamide, doxorubicin, 5-flourouracil;
FAC, 5-flouroracil, doxorubicin, cyclophosphamide; DAC, Docetaxel, doxorubicin, cyclophosphamide; T, Paclitaxel; D, Docetaxel; E, Epirubicin
*Hazard ratios were not reported in the manuscript; however P values did not reveal any statistical significance between study arms
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Paclitaxel was originally isolated from the bark of the
Pacific yew tree taxus brevifolia, and its antitumor activity
was initially described in 1971 [59]. Paclitaxel binds to
microtubules and induces their stabilization by inhibiting
their depolymerization, thereby leading to mitotic arrest
[60, 61] and chromosome missegregation on abnormal
multipolar spindles [62, 63]. Despite its unique mechanism
of action, paclitaxel’s initial development was slow due to
its scarcity and poor solubility. A formulation of paclitaxel
solubilized in Cremophor EL was eventually developed but
was associated with hypersensitivity reactions to the Cre-
mophor EL vehicle [64], requiring premedication with cor-
ticosteroids and histamine blockers, which nearly thwarted
paclitaxel’s clinical development. In 1994, Cremophor-EL-
paclitaxel was approved by the United States Food and
Drug Administration (FDA) for treatment of meta-
static breast cancer in patients who had progressed
after anthracycline-based combination chemotherapy or
who relapsed less than 6 months after adjuvant therapy
[64]. In order to address the initial scarcity of paclitaxel,
docetaxel, a semi-synthetic agent derived from the needles
of the European yew tree taxus baccata, was developed
[65]. Docetaxel has a similar mechanism of action to pacli-
taxel, but is a more potent microtubule inhibitor in vitro
[65]. Docetaxel is also slightly more water-soluble than
paclitaxel, and is dissolved in polysorbate-80. Despite the
different solvent, premedication is also required to reduce
the risk of acute hypersensitivity reactions and cumulative
fluid retention associated with docetaxel infusions [66]. A
direct comparison of docetaxel with paclitaxel in meta-
static breast cancer showed greater efficacy for docetaxel
but more toxicity [67], whereas a direct comparison of
paclitaxel with doxorubicin as first line therapy showed
comparable efficacy [68]. Both of these agents have been
extensively tested in adjuvant trials based upon substantial
single agent activity for each agent in metastatic breast
cancer [69].
First-generation chemotherapy regimen
Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
CMF was the first combination adjuvant chemotherapy
regimen that was tested in a prospective clinical trial
(Table 3). This trial, initiated in 1973 by the Istituto
Nazionale Tumori in Milan, Italy, randomized node
positive patients after radical mastectomy to 12 cycles
of cyclophosphamide (100 mg/m2 orally on days 1–14),
methotrexate (40 mg/m2 IV on days 1 and 8), and 5-
fluorouracil (600 mg/m2 IV on days 1 and 8) administered
every 28 days versus no additional treatment [22]. The
updated 342-month follow-up reported an improved
disease-free survival (DFS; hazard ratio (HR), 0.71; P =
0.005) and overall survival (OS; HR, 0.79; P = 0.04) for
CMF compared with the control population. Anotherimportant finding was that relapse rate was no different
when pre-menopausal women were compared to post-
menopausal women. A subsequent study demonstrated
that six cycles was as effective 12 cycles of adjuvant CMF
[70], with results sustained after long-term follow-up [71].
A study conducted by the US Breast Cancer Intergroup
found that six cycles of adjuvant CMF was also effective in
reducing the risk of recurrence and improving survival in
axillary node-negative disease [24, 25]. For patients with
ER-positive, lymph node-negative disease at lower risk for
recurrence, the NSABP B-20 trial found that the addition
of CMF to tamoxifen improved 5-year DFS (HR, 0.65;
P = 0.001) and OS (HR, 0.64; P = 0.03) [26]. The EBCTCG
meta-analysis found that adjuvant CMF reduced the risk
of recurrence by 30 % at 10 years (HR, 0.70; P <0.00001),
which translated into an absolute gain of 10.2 %. The
10-year overall mortality risk was reduced by 16 % (HR,
0.84; P <0.0004), which translated into an absolute gain
of 4.7 % at 10 years [16].
Doxorubicin and cyclophosphamide (AC)
One of the first adjuvant trials evaluating doxorubicin
was NSABP B-11, which compared melphalan and 5-
fluorouracil with or without doxorubicin in 697 non-
tamoxifen responsive patients (defined as women 50–59
years with a tumor PR level by ligand binding assay of 0–9
fmol, and all patients ≤49 years), and found an improved
5-year DFS (HR, 0.65; P = 0.007) and a trend to improved
OS (HR, 0.74; P = 0.08) for the doxorubicin arm [72]. In
order to find a more intense and shorter chemotherapy
regimen, the NSABP B-15 trial randomized 2,194 patients
with node-positive disease to AC (doxorubicin 60 mg/m2
and cyclophosphamide 600 mg/m2 every 3 weeks for four
cycles) given over 12 weeks versus conventional CMF
for six cycles over 24 weeks (Table 3). The 3-year DFS
rates (62 % vs 63 %; P = 0.5) and OS rates (83 % vs 82 %;
P = 0.8) were similar [73]. Subsequently, the NSABP B-23
trial showed no difference in outcomes in patients who
were treated with CMF or AC in patients with node-
negative disease [74]. The EBCTCG meta-analysis found
that comparison of CMF with AC yielded similar results
for breast cancer mortality (HR, 0.98; P = 0.67) [16]. Other
studies have found no advantage to administration of
six compared to four cycles of AC, and superiority for
AC compared with single agent paclitaxel given every 2
or 3 weeks [75].
5-Flourouracil, epirubicin (50 mg/m2), and
cyclophosphamide (FEC50)
The French Adjuvant Study Group (FASG) compared
epirubicin-based chemoendocrine therapy with tamoxifen
alone in 457 postmenopausal women with ER-positive
breast cancer and 1–3 positive nodes enrolled in two trials
(FASG 2 and 7) [76]. The chemotherapy regimen was
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cyclophosphamide 500 mg/m2), which was given every
3 weeks for six cycles concurrently with tamoxifen. The 9-
year DFS rates were 72 % with tamoxifen and 84 % with
FEC50-tamoxifen (HR, 0.46; P = 0.0008). The 9-year OS
rates were 78 % and 86 %, respectively (P = 0.11). In the
multivariate model, there was a trend in favor of che-
moendocrine therapy for OS (HR, 0.65; P = 0.07).
Second generation chemotherapy regimens
5-Flourouracil, epirubicin (100 mg/m2), and
cyclophosphamide (FEC100)
After randomized trials demonstrated a dose–response
relationship for epirubicin in metastatic breast cancer
[58, 77], the FASG05 compared adjuvant fluorouracil
(500 mg/m2) and cyclophosphamide (500 mg/m2) with
epirubicin given at 50 mg/m2 (FEC50) or 100 mg/m2
(FEC100) every 21 days for six cycles (FEC50) [78]. After
5 years of follow-up, FEC100 showed improved DFS
(HR, 0.63; P = 0.02) and OS (HR, 0.45; P = 0.005) compared
to FEC50 [78] (Table 3).
Cyclophosphamide, doxorubicin, and 5-fluorouracil
(CAF or FAC)
CAF is an acronym that is used to describe regimens in
which cyclophosphamide is administered orally for 14 days
and doxorubicin and 5-fluorouracil are given on days 1 and
8 every 28 days for six cycles, whereas FAC is an acronym
used to describe a regimen in which all of these agents are
given IV every 3 weeks for six cycles. The SWOG-8814/
INT-0100 trial randomized postmenopausal women with
hormone-receptor positive, node-positive breast cancer to
CAF plus tamoxifen versus tamoxifen alone. DFS was su-
perior for CAF plus tamoxifen (HR, 0.76; P = 0.002), but
OS was only marginally improved (HR, 0.83; P = 0.057)
[23]. The EBCTCG meta-analysis found that breast cancer
mortality rates were reduced more with FAC for six cycles
(HR, 0.64; P <0.0001) than AC for four cycles (HR, 0.78;
P = 0.01) or CMF for six cycles (risk ratio, 0.76; P <0.0001)
[16], and that FAC or FEC combinations were more effect-
ive in reducing breast cancer mortality compared to CMF
(risk ratio, 0.78; P = 0.0004) [16].
Sequential doxorubicin/cyclophosphamide followed by
paclitaxel (AC-T)
Concurrent administration of paclitaxel and doxorubicin,
two of the most active cytotoxic agents for metastatic
breast cancer, was associated with substantial activity,
but led to prohibitive cardiotoxicity due to a pharmaco-
kinetic interaction resulting in greater doxorubicin expos-
ure [79]. In addition, mathematical modeling predicted that
sequential administration of cytotoxic agents at their opti-
mal doses would result in more effective antitumor activity
than their concurrent administration [80, 81]. Therefore,two phase 3 trials evaluated sequential administration of
paclitaxel after anthracycline-containing therapy (Table 3).
CALGB 9344 employed a 2 × 2 factorial design evaluating
escalating doses of doxorubicin (60, 75, or 90 mg/m2) in
combination with cyclophosphamide (600 mg/m2) every
21 days for four cycles, given alone, or followed sequentially
by four cycles of paclitaxel (175 mg/m2 IV every 21 days) in
3,121 patients with node-positive breast cancer. After a me-
dian follow-up of 69 months, the addition of paclitaxel was
associated with improved DFS (HR, 0.83; P = 0.0023) and
OS (HR, 0.82; P = 0.006). Escalation of doxorubicin dose
had no impact on outcomes [82]. In the NSABP B-28 trial,
after a median follow-up of 65 months, the sequential
addition of four cycles of paclitaxel (225 mg/m2) to
four cycles of AC in 3,060 patients with node-positive
breast cancer improved DFS (HR, 0.83; P = 0.006) but
not OS (HR, 0.93; P = 0.46) [83]. Endocrine therapy with
tamoxifen was given after chemotherapy in the C9344 trial
in patients with ER-positive disease, whereas it was given
concurrently with chemotherapy in the B28 trial for pa-
tients 50 years of age or older, and those younger than 50
with ER- and/or PR-positive tumors. Other studies have
suggested greater benefit from adjuvant chemotherapy
in postmenopausal women with ER-positive disease when
tamoxifen is initiated sequentially following completion
of chemotherapy [23]. The results of the C9344 study
supported FDA approval of adjuvant paclitaxel in the US.Sequential epirubicin followed by CMF
The National Epirubicin Adjuvant Trial (NEAT) and
BR9601 trials evaluated the efficacy of epirubicin followed
by CMF. The BR9601 trial used a modified CMF regimen
(cyclophosphamide 750 mg/m2, methotrexate 50 mg/m2,
and 5-flouorouracil 600 mg/m2 on day 1 every 3 weeks)
whereas the NEAT trial used classic CMF. Both trials
compared four cycles of epirubicin 100 mg/m2 every
3 weeks followed by four cycles of CMF (epirubicin-CMF)
versus CMF alone (six cycles in NEAT, eight cycles in
BR9601). Combined analysis included 2,391 patients. After
a median follow-up of 48 months, epirubicin-CMF group
was associated with improved DFS (HR, 0.69; P <0.001)
and OS (HR, 0.67; P <0.001) compared to CMF alone [84].Docetaxel plus cyclophosphamide
The US Oncology Research phase III trial evaluated 1,016
patients with operable breast cancer who were assigned
to four 3-week cycles of AC (doxorubicin 60 mg/m2
and cyclophosphamide 600 mg/m2) or DC (docetaxel
75 mg/m2 and cyclophosphamide 600 mg/m2) [85]
(Table 3). After a median follow-up of 84 months, DC
was associated with significantly improved DFS (HR,
0.74; P = 0.033) and OS (HR, 0.69; P = 0.032).
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Docetaxel, doxorubicin, and cyclophosphamide (DAC)
Unlike paclitaxel, docetaxel does not have a major phar-
macokinetic interaction with doxorubicin, and does not
increase doxorubicin-related cardiotoxicity when given
concurrently [86–88]. Two studies compared a combin-
ation of docetaxel, doxorubicin, and cyclophosphamide
(DAC) with FAC (Table 3). The Breast Cancer Inter-
national Research Group 0001 trial compared six cycles
DAC (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, and
cyclophosphamide 500 mg/m2) with FAC (5-fluorouracil
500 mg/m2, doxorubicin 50 mg/m2, and cyclophospha-
mide 500 mg/m2) every 3 weeks as adjuvant treatment for
1,491 women with operable node-positive breast cancer
[89, 90]. After a median follow-up of 124 months, there
were improvements in DFS (HR, 0.80; P = 0.0043) and OS
(HR, 0.74; P = 0.002). The benefit in DFS was irrespective
of nodal, hormone receptor, and HER2 status. The GEI-
CAM 9805 trial compared six cycles of DAC with FAC in
1,060 patients with node-negative breast cancer [91]. After
a median follow-up of 77 months, there was a significant
improvement in DFS (HR, 0.68; P = 0.01) and a trend
toward improved OS (HR, 0.76; 95 % CI, 0.45 to 1.26;
P = 0.29) favoring DAC. In both trials, DAC was associ-
ated with considerably more toxicity, including febrile
neutropenia.
Sequential FEC-taxane therapy
Although it was clear that results improved when taxanes
were added sequentially following anthracyclines, it was
unclear as to whether this improvement was specifically
due to the sequential addition of a taxane, or due to more
prolonged duration of adjuvant chemotherapy administra-
tion. Three trials described herein directly addressed this
question by comparing an anthracycline-containing regi-
men and a sequential anthracycline-taxane regimen in
which the treatment arms had a comparable duration
(Table 3). The PACS01 trial evaluated six 3-week cycles of
FEC (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2,
and cyclophosphamide 500 mg/m2) with three cycles of
FEC followed by docetaxel (100 mg/m2 every 3 weeks) for
three cycles in 1,999 patients with node-positive breast
cancer [92]. After a median follow-up of 93 months, the
sequential taxane arm was associated with improved DFS
(HR, 0.85; P = 0.036) and OS (HR, 0.75; P = 0.007) [93].
The UK TACT study randomized 4,162 women with
node-positive or high-risk node-negative breast cancer to
four cycles of FEC followed by four cycles of docetaxel
(100 mg/m2 every 3 weeks) versus a control regimen
consisting of physician’s choice of eight cycles of FEC
(5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and
cyclophosphamide 600 mg/m2) or epirubicin for four
cycles followed by four cycles of CMF. After a median
follow-up of 62 months, there was no significant differencein outcome between the arms [94]. In the GEICAM 9906
trial, 1,246 patients with node-positive breast cancer pa-
tients were randomized to six cycles of FEC (5-fluorouracil
600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide
600 mg/m2) or four cycles of FEC followed by eight
weekly doses paclitaxel (100 mg/m2 per week). After a
median of 66 months, the sequential paclitaxel arm was
associated with a reduced risk of recurrence (HR, 0.77;
P = 0.022) and trend toward a lower risk of death (HR,
0.78; P = 0.110) [95].
The specific benefit of sequential addition of a taxane
was also addressed in the 2012 EBCTCG meta-analysis
[16]. In trials adding four separate cycles of a taxane to a
fixed anthracycline-based control regimen and extending
treatment duration, breast cancer mortality was reduced
(HR, 0.86; P = 0.0005). However, in trials with four such
extra cycles of a taxane counterbalanced in controls by
extra cycles of other cytotoxic drugs, roughly doubling
non-taxane dosage, there was no significant difference in
breast cancer mortality (HR, 0.94; P = 0.33). Although these
results would suggest similar benefits for a 24- compared
to a 12-week adjuvant cytotoxic regimen irrespective
of which agents are used, the sequential approach may
minimize the delayed effects of anthracyclines whose
risk increases with greater cumulative dose.
Dose dense sequential doxorubicin/cyclophosphamide-
paclitaxel (AC-T)
The concept of dose density has been also evaluated in
some adjuvant therapies for breast cancer. Dose density
refers to administering the same therapeutic regimen
(without changing actually doses given) at more frequent
intervals, with the goal of decreasing the time for cancer
cells to recover in between chemotherapy cycles [80, 96].
The C9741 assessed the impact of dose density (2 week
vs 3 week) and treatment sequence (concurrent vs se-
quential) in patients with operable breast cancer by
randomizing 2,005 patients to four different treatment
arms using a 2 × 2 factorial design to: (1) concurrent
AC-T (paclitaxel) versus sequential A-C-T and (2) every
3 weeks versus a dose-dense regimen every 2 weeks plus
filgrastim [97] (Table 3). At 36-month follow-up, the dose-
dense regimen improved the primary end-point DFS (HR,
0.74; P = 0.01) and OS (HR, 0.69; P = 0.013). There was no
difference in either DFS or OS between the concurrent
and sequential schedules [97]. Updated results after a me-
dian 6.5 years of follow-up continue to favor dose-dense
chemotherapy in DFS (HR, 0.80; P = 0.01) and OS (HR,
0.85; P = 0.04) [98]. The dose-dense schedule was associ-
ated with improved DFS (HR, 0.76; P =0.01) and OS (HR,
0.79; P = 0.04) in ER-negative disease but not ER-positive
disease.
A systemic review and meta-analysis identified 10 trials
that met the inclusion criteria for evaluating the effect of
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enrolling 3,337 patients, compared dose-dense chemo-
therapy with a conventional chemotherapy schedule
(similar agents). Patients who received dose-dense chemo-
therapy had improved OS (HR, 0.84; P = 0.03) and DFS
(HR, 0.83; P = 0.005) compared with those who received
the conventional schedule, although no benefit was
observed in patients with hormone receptor-positive
tumors. Seven trials, enrolling 8,652 patients, com-
pared dose-dense chemotherapy with regimens that
use standard intervals but with different agents and/or
dosages in the treatment arms. Similar results were
obtained for these trials with respect to OS (HR, 0.85;
P = 0.01) and DFS (HR, 0.81; P <0.001). The rate of
non-hematological adverse events was higher in the
dose-dense chemotherapy arms than in the conven-
tional chemotherapy arms.Sequential AC-weekly paclitaxel or every 3 week docetaxel
The ECOG E1199 trial was designed to identify the opti-
mal taxane and schedule. This trial enrolled 4,954 patients
with stage II–III breast cancer who received standard AC
followed sequentially by taxane therapy using a 2 × 2 fac-
torial design. The study found no difference in the primary
comparisons of taxane (paclitaxel vs docetaxel) and sched-
ule (every 3 weeks vs weekly); other pre-specified analyses
included a comparison of the standard every 3 week pacli-
taxel arm (175 mg/m2) for four cycles (P3 control arm)
with weekly paclitaxel (80 mg/m2) for 12 weeks (P1 arm),
docetaxel (100 mg/m2) every 3 weeks for four cycles
(D3 arm), or weekly docetaxel (35 mg/m2) for 12 weeks
(D1 arm) [100]. After a median follow-up of 5.3 years,
the P1 arm was associated with improved DFS (HR,
0.73; P = 0.006) and OS (HR, 0.68; P = 0.01) compared
with the P3 arm. Although improved DFS was also ob-
served for the D3 arm (HR, 0.77; P = 0.02) without a
survival benefit, it was associated with substantially
more toxicity than the P1 arm. In an updated analysis
after a median follow-up of 12.1 years, DFS was signifi-
cantly improved and OS marginally improved for both
the P1 arm (HR, 0.84; P = 0.011 and HR, 0.87; P = 0.09,
respectively) and D3 arm (HR, 0.79; P = 0.001 and HR,
0.86; P = 0.054, respectively). Although weekly pacli-
taxel improved DFS and OS (HR, 0.69; P = 0.010 and
HR, 0.69; P = 0.019, respectively) in triple negative breast
cancer, no experimental arm improved OS for hormone
receptor-positive, HER2 non-overexpressing breast cancer
[101]. Another trial found no difference in outcomes
comparing weekly paclitaxel (80 mg/m2 for 12 doses)
with biweekly paclitaxel given at a higher dose (175 mg/m2
for six doses) given sequentially after AC, although there
was more toxicity with biweekly higher dose paclitaxel
schedule [102].Sequential versus concurrent taxane administration
The NSABP B30 trial addressed the question of whether
docetaxel is best given concurrently with or sequentially
following doxorubicin [103]. The study included 5,351
patients with node-positive breast cancer to receive four
cycles of AC followed by four cycles of docetaxel (sequen-
tial AC-D), four cycles of doxorubicin and docetaxel (AD),
or four cycles of doxorubicin, cyclophosphamide, and do-
cetaxel (concurrent DAC). After a median follow-up of
73 months, DFS was improved in the sequential-AC-D
arm compared with the AD (HR, 0.80; P = 0.001) and the
concurrent DAC arm (HR, 0.83; P = 0.01), and OS was
likewise improved in the sequential-ACD arm compared
with the AD arm (HR, 0.83; P = 0.03) and concurrent
DAC arm (HR, 0.86; P = 0.09).
Predicting benefit from chemotherapy
In the EBCTC meta-analyses involving taxane-based or
anthracycline-based regimens, proportional reductions in
risk of recurrence associated with adjuvant chemotherapy
were little affected by age, nodal status, tumor diameter or
grade, ER expression, or tamoxifen use, and breast cancer
mortality was reduced on average by one-third [16]. Sev-
eral multiparameter gene expression assays have been
shown to provide prognostic information in patients with
ER-positive breast cancer [7, 8] and also identify which pa-
tients derive greatest benefit from adjuvant chemotherapy
[29, 30]. Currently available assays include the Oncotype
DX® (Genomic Health, Inc., Redwood City, CA), Mam-
maPrint® (Agendia, Inc. USA, Irvine, CA), Prosigna®
(Nanostring Technologies, Seattle, WA), and Breast Cancer
IndexSM (bioTheranostics, Inc., San Diego, CA). Some
of these assays are endorsed by evidence-based guide-
lines for making clinical decisions regarding the use of
adjuvant chemotherapy in specific settings [31]. Never-
theless, the assays may not inform treatment decisions
in up to approximately 50 % of those tested [104]. Ran-
domized trials are in progress in order to determine
whether chemotherapy may be safely spared in patients
with tumors associated with low risk signatures who would
otherwise have been advised to receive chemotherapy based
on classic clinicopathologic features [105, 106]. For
example, in the Trial Assigning Individualized Options
for Treatment (TAILORx) (NCT00310180), patients
with ER-positive, HER2-negative, axillary node negative
disease who meet National Comprehensive Cancer Center
Network guidelines for recommending adjuvant chemo-
therapy are assigned to endocrine therapy alone if the
Oncotype DX Recurrence Score (RS) is very low (<11)
or chemoendocrine therapy if the RS is in the high or
high-intermediate range (>25), and are randomized to
chemoendocrine therapy versus endocrine therapy if there
is a mid-range RS of 11–25[105]. Likewise, in the clinical
trial for treatment of endocrine responsive breast cancer
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positive axillary nodes are assigned to chemoendocrine
therapy if the RS >25 and randomized to chemoendocrine
therapy versus endocrine therapy if the RS is <26 (https://
clinicaltrials.gov/ct2/show/NCT01272037). The cut points
used in these trials differ from the originally classifica-
tion of low (RS <18), intermediate (RS18-30), and high
(RS >30) in order to minimize the potential for chemo-
therapy under-treatment [105].
Tailoring the optimal regimen for individual patients
Factors considered in selecting patients for adjuvant ther-
apy include tumor-specific factors, such as tumor size, ax-
illary node metastasis, and tumor biology (i.e. ER/PR and
HER2 expression, multiparameter gene expression assays),
and patient specific factors such as age, comorbidities, and
patient preference. A risk classification and potential
therapeutic options for each risk category is proposed in
Table 4. Patients with T1a tumors (1–5 mm) and negative
nodes are at very low-risk of recurrence and generally do
not require systemic chemotherapy. Patients with inter-
mediate or high-risk disease should receive chemotherapy,
whereas those with low-risk disease may be considered for
chemotherapy if younger (<50–60 years). Patients with
high-risk disease requiring chemotherapy are usually ad-
vised to receive an anthracycline and taxane containing
regimen (i.e. third generation regimen), whereas those
with low or moderate-risk disease may be treated with a
taxane-containing regimen without an anthracycline (i.e.
second generation regimen). All patients with ER- and/or
PR-positive disease should always receive at least a 5-year
course of endocrine therapy, usually initiated after chemo-
therapy is completed if given. Patients with HER2-positive
disease should also always receive trastuzumab in com-
bination with chemotherapy. Although data for adjuvantTable 4 Commonly recommended adjuvant chemotherapy regimen
Recurrence risk
category and definition
Recommended regimens: ER-positive, HER2-negativ
Very low risk
• Node-Neg, T1a No chemotherapy
Low risk
• Node-Neg, T1b Consider second generation chemotherapy regime
RS is high
• Node-Neg, T1c, Second generation chemotherapy regimen if RS is
(or consider if intermediate)
Moderate risk
• Node-Neg, T2 Second or third generation chemotherapy regimen
RS intermediate-high
High risk
• 1+ Pos Nodes or T3 Third generation chemotherapy regimen if RS interm
high (or 4+ positive nodes irrespective of RS)
TCH, Docetaxel, carboplatin, trastuzumab; T, Paclitaxel; AC, Doxorubicin, cyclophosp
Recurrence score.pertuzumab is currently lacking, it is recommended by
National Comprehensive Cancer Center Network guide-
lines as a component of adjuvant therapy [107] for
high-risk HER2-positive breast cancer based on improved
survival when used in metastatic HER2-postive breast can-
cer [108], and improved pathologic complete response
when used in locally advanced breast cancer [109]. On the
other hand, other expert panels do not recommend use of
adjuvant pertuzumab until results of the APHINITY trial
(NCT01358877) become available [110], an adjuvant trial
designed to determine whether adding pertuzumab to
adjuvant trastuzumab-chemotherapy regimen improves
clinical outcomes.
Conclusions
Localized and regionally advanced breast cancer is a po-
tentially curative disease with local therapy alone, and
adjuvant systemic chemotherapy, endocrine therapy, and
anti-HER2 directed therapy substantially reduce the risk
of distant recurrence and breast cancer mortality. Acute
reversible effects associated with chemotherapy include
alopecia, nausea, vomiting, fatigue, and myelosuppres-
sion, whereas long-term potentially irreversible effects
include cardiomyopathy, acute leukemia, and neuropathy
[111]. The choice of chemotherapy regimen may be in-
dividualized based upon disease-specific factors such as
the underlying risk of recurrence and the projected
relative and absolute benefits from chemotherapy, as
well as patient-specific factors such as age, comorbidities,
and risk tolerance. Decision aids may be helpful in allowing
patients and caregivers to make more informed decisions
about the potential benefits of adjuvant chemotherapy, and
multiparameter gene expression assays may allow more ac-
curate estimates of the potential benefits of such therapy.
The TAILORx, MINDACT, RxPONDER, and OPTIMAs




No chemotherapy No chemotherapy




high Second generation chemotherapy
regimen
Weekly paclitaxel + H
or TCH
if Third generation chemotherapy
regimen
AC-T + H or TCH +/− P
ediate- Third generation chemotherapy
regimen
AC-T + H or TCH+/−P
hamide; H, Trastuzumab; P, Pertuzumab; Neg, Negative; Pos, Positive; RS,
Anampa et al. BMC Medicine  (2015) 13:195 Page 10 of 13trials are evaluating the incorporation of multiparameter
gene expression assays into clinical decision making to
tailor adjuvant treatment among patients with breast
cancer. Improvements in adjuvant cytotoxic regimens
have contributed to declining breast cancer mortality
rates and clinical trials are underway that may serve to
identify subgroups deriving the greatest benefits from
such therapy.
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